Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263

Oliver A. Cornely, Michael N. Robertson, Shariq Haider, Andrew Grigg, Michelle Geddes, Mickael Aoun, Werner J. Heinz, Issam Raad, Urs Schanz, Ralf G. Meyer, Sarah P. Hammond, Kathleen M. Mullane, Helmut Ostermann, Andrew J. Ullmann, Stefan Zimmerli, M. L.P.S.Van Iersel, Deborah A. Hepler, Hetty Waskin, Nicholas A. Kartsonis, Johan Maertens

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Erratum: Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease [J Antimicrob Chemother, 72, (2017) (3406-3413)] doi: 10.1093/jac/dkx263'. Together they form a unique fingerprint.